Researchers are excited about this new drug, a groundbreaking dual agonist showing remarkable results in early trials for body reduction . It functions by impacting two pathways : GLP-1 and GIP, these, when stimulated, help regulate cravings and improve metabolism . Early findings indicate noteworthy size reduction and likely benefits for patients